- Home
- MIRM vs FBIN Comparison
MIRM vs FBIN Comparison
Compare MIRM & FBIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | FBIN |
|---|---|---|
| Founded | 2018 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building Products |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 5.5B |
| IPO Year | 2019 | 2011 |
Fundamental Metrics
Financial Performance| Metric | MIRM | FBIN |
|---|---|---|
| Price | $122.61 | $50.88 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 11 |
| Target Price | ★ $119.85 | $54.60 |
| AVG Volume (30 Days) | 855.5K | ★ 2.3M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.58% |
| EPS Growth | ★ 74.59 | N/A |
| EPS | N/A | ★ 0.20 |
| Revenue | $19,138,000.00 | ★ $4,463,200,000.00 |
| Revenue This Year | $26.22 | $2.68 |
| Revenue Next Year | $22.04 | $3.60 |
| P/E Ratio | ★ N/A | $229.80 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $47.89 | $32.34 |
| 52 Week High | $124.44 | $64.84 |
Technical Indicators
Market Signals| Indicator | MIRM | FBIN |
|---|---|---|
| Relative Strength Index (RSI) | 77.72 | 74.58 |
| Support Level | $87.93 | $49.02 |
| Resistance Level | N/A | $53.19 |
| Average True Range (ATR) | 5.12 | 2.15 |
| MACD | 2.70 | 0.79 |
| Stochastic Oscillator | 92.41 | 98.08 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About FBIN Fortune Brands Innovations Inc.
Fortune Brands is a US-based homebuilding products company that sells building-related products serving R&R and new construction markets. The company operates in three segments: water, outdoors, and security. Water innovation, including plumbing fixtures and faucets, accounts for around 55% of total sales and features brands such as Moen, House of Rohl, and Aqualisa. The outdoors segment includes decking, railing, and doors and makes up 30% of total sales, featuring brands such as Larson, Fiberon, and Therma-Tru. The security segment, which includes smart residential padlocks, accounts for the remaining 15% of sales and features brands such as MasterLock, SentrySafe, Yale, and AmericanLock.